Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncogenic mutations in XPO1 promote lymphoid transformation by altering nuclear/cytoplasmic localization of NFκB signaling intermediates
    Meeting Abstract

    Taylor, J.; Zhang, X. J.; Paffenholz, S. V.; Penson, A. V.; Chang, M.; Marcelus, C.; Bitner, L. E.; Chung, Y. R.; Yoshimi, A.; Lee, S. C. W.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations
    Meeting Abstract

    Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S. M.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo Coco, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML
    Meeting Abstract

    Stone, R. M.; Choe, S.; Zhang, V.; Marteyn, B.; Penard-Lacronique, V.; Wang, H.; DiNardo, C. D.; Stein, E. M.; Fathi, A. T.; Tallman, M. S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Characterization of NTRK fusions and therapeutic response to NTRK inhibition in hematologic malignancies
    Meeting Abstract

    Taylor, J.; Marcelus, C.; Pavlick, D.; Benayed, R.; Yoshimi, A.; Cocco, E.; Durham, B. H.; Hechtman, J. F.; Chung, Y. R.; Mullaney, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time
    Meeting Abstract

    Stein, E. M.; Stone, R. M.; Pollyea, D. A.; Roboz, G. J.; Altman, J. K.; DiNardo, C. D.; de Botton, S.; Tu, N.; Swern, A. S.; Tosolini, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in the United States
    Meeting Abstract

    Stein, E. M.; Xie, J.; Duchesneau, E.; Bhattacharyya, S.; Ndife, B.; Bonifacio, G.; Joseph, G. J.
    Blood (2017)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE)
    Meeting Abstract

    Shah, N. P.; Gutiérrez, J. V. G.; Jiménez-Velasco, A.; Larson, S. M.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M.; Gómez-Casares, M. T.; Pane, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic landscapes in elderly AML
    Meeting Abstract

    Rapaport, F.; Baslan, T.; Wang, L.; Sheridan, C.; Lee, T.; Hricik, T.; de Massy, M. R.; Telis, L.; Neelamraju, Y.; Medina, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Results from ENESTgoal: A phase 2 study of treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who switched from imatinib to nilotinib
    Meeting Abstract

    Ritchie, E. K.; Catchatourian, R.; Klisovic, R. B.; Pinilla-Ibarz, J.; Deininger, M. W.; Erba, H. P.; Radich, J. P.; Savona, M. R.; Dautaj, I.; Purkayastha, D.; more...
    Blood (2017)

    Fulltext@MSK | Save